|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SCN11A |
Gene summary for SCN11A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SCN11A | Gene ID | 11280 |
| Gene name | sodium voltage-gated channel alpha subunit 11 | |
| Gene Alias | FEPS3 | |
| Cytomap | 3p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0001508 | UniProtAcc | Q9UI33 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11280 | SCN11A | HCC1 | Human | Liver | HCC | 3.08e-17 | 1.59e+00 | 0.5336 |
| 11280 | SCN11A | HCC2 | Human | Liver | HCC | 7.99e-32 | 2.19e+00 | 0.5341 |
| 11280 | SCN11A | HCC5 | Human | Liver | HCC | 1.97e-27 | 1.88e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SCN11A | SNV | Missense_Mutation | novel | c.4540C>A | p.Leu1514Met | p.L1514M | Q9UI33 | protein_coding | deleterious(0) | possibly_damaging(0.522) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| SCN11A | SNV | Missense_Mutation | novel | c.580N>A | p.Pro194Thr | p.P194T | Q9UI33 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | |
| SCN11A | SNV | Missense_Mutation | c.57N>A | p.Phe19Leu | p.F19L | Q9UI33 | protein_coding | deleterious(0.02) | benign(0.184) | TCGA-A2-A04R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD | |
| SCN11A | SNV | Missense_Mutation | c.3163C>A | p.His1055Asn | p.H1055N | Q9UI33 | protein_coding | deleterious(0.03) | possibly_damaging(0.642) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SCN11A | SNV | Missense_Mutation | c.5077N>A | p.Val1693Ile | p.V1693I | Q9UI33 | protein_coding | deleterious(0.01) | probably_damaging(0.94) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SCN11A | SNV | Missense_Mutation | c.5069C>A | p.Thr1690Asn | p.T1690N | Q9UI33 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A082-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| SCN11A | SNV | Missense_Mutation | novel | c.3990G>T | p.Lys1330Asn | p.K1330N | Q9UI33 | protein_coding | deleterious(0) | benign(0.046) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
| SCN11A | SNV | Missense_Mutation | c.3964N>A | p.Asp1322Asn | p.D1322N | Q9UI33 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SCN11A | SNV | Missense_Mutation | rs772016847 | c.5371N>C | p.Asp1791His | p.D1791H | Q9UI33 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-B6-A0RT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SCN11A | SNV | Missense_Mutation | rs764550088 | c.742C>T | p.Arg248Cys | p.R248C | Q9UI33 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 11280 | SCN11A | DRUGGABLE GENOME, ION CHANNEL, KINASE | blocker | CHEMBL3545209 | NKTR-171 | |
| 11280 | SCN11A | DRUGGABLE GENOME, ION CHANNEL, KINASE | blocker | CHEMBL918 | PHENACEMIDE | |
| 11280 | SCN11A | DRUGGABLE GENOME, ION CHANNEL, KINASE | blocker | CHEMBL1200341 | INDECAINIDE HYDROCHLORIDE | |
| 11280 | SCN11A | DRUGGABLE GENOME, ION CHANNEL, KINASE | blocker | CHEMBL1201754 | RUFINAMIDE | |
| 11280 | SCN11A | DRUGGABLE GENOME, ION CHANNEL, KINASE | Tolperisone | TOLPERISONE | ||
| 11280 | SCN11A | DRUGGABLE GENOME, ION CHANNEL, KINASE | blocker | CHEMBL1201022 | PHENAZOPYRIDINE HYDROCHLORIDE | |
| 11280 | SCN11A | DRUGGABLE GENOME, ION CHANNEL, KINASE | blocker | CHEMBL1194 | PRILOCAINE | |
| 11280 | SCN11A | DRUGGABLE GENOME, ION CHANNEL, KINASE | blocker | CHEMBL919 | FOSPHENYTOIN SODIUM | |
| 11280 | SCN11A | DRUGGABLE GENOME, ION CHANNEL, KINASE | blocker | CHEMBL1200440 | MEPIVACAINE HYDROCHLORIDE | |
| 11280 | SCN11A | DRUGGABLE GENOME, ION CHANNEL, KINASE | Lidocaine | LIDOCAINE |
| Page: 1 2 3 4 5 6 7 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |